SEC Form 4/A · accession 0000914190-15-000364
BIO-TECHNE Corp · TECH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Norman David Eansor
Officer — SVP - Novus Biologicals
Period of report
Aug 7, 2015
Accepted (ET)
Aug 20, 2015 · 6:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000842023
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $108.49 | Aug 7, 2015 | A | 9,375 | A | — | Aug 7, 2022 | Common Stock | 9,375 | 9,375 | D |
| Restricted Stock UnitsF2,F1 | — | Aug 7, 2015 | A | 1,500 | A | — | — | Common Stock | 1,500 | 1,500 | D |
Explanation of responses
- F1Vests in full or in part if certain performance goals are achieved during each of the 2016, 2017 and 2018 fiscal years.
- F2Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
Remarks
On August 20, 2015, a Form 4 was filed that did not contain the information required by Box 4 to indicate an amendment to a prior report. The amendment was being filed solely to correct the number of options and restricted stock units granted on August 7, 2015 as initially reported on August 11, 2015.